Search Results
Your search for ,WHo matches 20933 pages
Showing 1 - 50A Paradigm Shift In Treating Adult AML?
The scientific revolution in determining the genetic basis of cancer is finally bearing fruit in hematologic neoplasms such as acute myeloid leukemia (AML), where over the past decade a number of effective new drugs have expanded our armamentarium and provided effective—and in some cases...
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
Breakthrough research presented at the 2026 Society of Thoracic Surgeons (STS) Annual Meeting shows that additional lymph node evaluation is needed during surgery for non–small cell lung cancer (NSCLC) to accurately identify cancer spread (Abstract A-1588). Globally, surgical standards vary on the...
Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans
Exposure to Agent Orange in U.S. veterans was associated with an increased odds of developing acral melanoma compared with controls with and without cutaneous melanoma, according to findings published in JAMA Dermatology. The study authors suggested that there is a need for continued investigation ...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
WHO Analysis Finds Nearly 40% of Global Cancer Cases Attributable to Modifiable Risk Factors
Almost 40% of all new cancer cases could be attributed to at least one of 30 modifiable risk factors, according to a new global analysis from the World Health Organization (WHO) and its International Agency for Research on Cancer (IARC). The analysis of preventable cancers was published in Nature...
Jame Abraham, MD, FACP, on HER2-Positive Metastatic Breast Cancer: Choosing a Regimen in Clinical Practice
Jame Abraham, MD, FACP, puts findings from several trials in HER2-positive breast cancer into context, including HER2CLIMB, which investigated tucatinib, trastuzumab, and capecitabine in pretreated patients with metastatic disease; DESTINY Breast-09, which evaluated fam-trastuzumab deruxtecan-nki...
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing datasets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma....
World Cancer Day 2026: UICC’s Campaign ‘United by Unique’
As the organizer of World Cancer Day on February 4, the Union for International Cancer Control (UICC) is mobilizing organizations and individuals worldwide to ensure that the voices of people affected by cancer are heard and drive a new vision of cancer care. Now in its second year, the World...
Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer
In a phase III trial (PATINA) reported in The New England Journal of Medicine, Metzger et al found that the addition of palbociclib to anti-HER2 and endocrine therapies significantly prolonged progression-free survival in patients with hormone receptor–positive, HER2-positive metastatic breast...
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
The use of oxybutynin led to statistically significant reductions in the number of hot flashes per day compared with placebo for men with prostate cancer receiving androgen-deprivation therapy (ADT), according to findings from the Alliance A222001 trial published in the Journal of Clinical...
Case 3: Management of Multiply Relapsed DLBCL
This is Part 3 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the treatment of multiply relapsed...
Case 2: Second-Line Management of Relapsed DLBCL
This is Part 2 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the second-line treatment of relapsed ...
Case 1: Management of Early Relapsed DLBCL
This is Part 1 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the treatment of early relapsed...
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the...
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
New Four-Biomarker Blood Panel May Improve Early Detection of Pancreatic Cancer
Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, and is most often diagnosed at advanced, unresectable stages, when 5-year survival is just 3%. The results from two retrospective phase II studies investigating blood biomarkers to detect early-stage pancreatic ductal...
AI Tool May Predict Cardiac Events in Patients With Cancer and Acute Coronary Syndrome
An artificial intelligence (AI)-based risk prediction model, ONCO-ACS, showed possible favorable clinical utility as a practical tool for predicting cardiovascular death, myocardial infarction, and ischemic stroke events in patients with cancer and acute coronary syndrome, according to findings...
Adjuvant Aumolertinib in EGFR-Mutated NSCLC
As reported in The Lancet Oncology by Zhang et al, the Chinese phase III ARTS trial showed superior disease-free survival with the third-generation EGFR tyrosine kinase inhibitor aumolertinib as adjuvant therapy vs placebo in patients with completely resected stage II to IIIB EGFR-mutated non–small ...
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy. Findings from the De-Squamate study were published in the...
Deep-Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
Sako et al conducted a prognostic study to evaluate whether a fully automated deep-learning radiomic biomarker based on serial CT scans could improve prediction of overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors. Their findings,...
Head and Neck Cancer: How Does Genetic Ancestry Impact Tumor Genomics?
Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African American patients survive for half as long as their counterparts of European ancestry, according to a new review study published by Ndahayo et al in Cancer and Metastasis Reviews....
AACR Announces Fellows of the AACR Academy Class of 2026
The American Association for Cancer Research (AACR) has announced its newly elected 2026 class of Fellows of the AACR Academy. The Fellows of the AACR Academy was established to honor scientists, clinicians, and physician-scientists whose visionary work has reshaped the landscape of cancer...
Machine Learning–Enhanced Prognostic Scoring Predicts Survival and Classifies Risk From Spinal Metastases
A prognostic scoring system for predicting 1-year survival in patients with advanced cancer and spinal metastases was enhanced with machine learning for greater accuracy, according to the results of a Japanese multicenter study published in Spine. "This model provides a practical risk assessment...
American College of Surgeons Publishes Annual NCDB Report
The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a substantial rise in neoadjuvant treatments, such as chemotherapy, immunotherapy, and hormone therapy, often allowing for less invasive surgery and helping clinicians assess how a...
Advanced NSCLC: Dual vs Single Checkpoint Blockade
A global meta-analysis combined detailed patient data from six major clinical trials to compare two types of immunotherapies for advanced non–small cell lung cancer (NSCLC): dual immunotherapy (a combination of CTLA-4 and PD-1/PD-L1 inhibitors) and single immunotherapy (PD-1/PD-L1 inhibitors...
Multiple Myeloma: FDA Approves Daratumumab and Hyaluronidase-fihj in Combination With VRd
On January 27, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous...
Outcomes With Colorectal Cancer Screening Among Childhood Cancer Survivors Who Received Abdominopelvic Radiation
In a study reported in the Journal of Clinical Oncology, Yeh et al found that childhood cancer survivors who received abdominopelvic radiation, who are at increased risk of developing colorectal cancer, can benefit from early screening to reduce the risk of colorectal cancer and associated...
CRI Launches Open Database for Immunotherapy Cancer Research
The Cancer Research Institute (CRI) in collaboration with 10x Genomics, Stanford University School of Medicine, the University of Pennsylvania Perelman School of Medicine, and Memorial Sloan Kettering Cancer Center, has launched an open foundational database for cancer immunotherapy research. The...
Colorectal Cancer: How Does Lifetime Alcohol Consumption Affect Risk?
Studies have demonstrated a link between alcohol consumption and an elevated risk of colorectal cancer. New research now reveals that higher lifetime alcohol consumption is also associated with a higher risk, especially for rectal cancer, and that quitting drinking can lower a person’s risk. The...
Cabozantinib and Temozolomide in Unresectable or Metastatic Leiomyosarcoma
In a phase II study reported in The Lancet Oncology, Monga et al found that dual targeting of vascular endothelial growth factor (VEGF) and mesenchymal epithelial transition factor receptor (MET) pathways with cabozantinib and temozolomide was of benefit in patients with unresectable or metastatic...
Leader in Global Cancer Care, Paul E. Goss, MD, PhD, Dies at 70
The oncology community is mourning the loss of Paul E. Goss, MD, PhD, who died on December 19, 2025, at his home in Hopkinton, Massachusetts, from multiple system atrophy—a rare, progressive neurologic disorder with symptoms resembling those of Parkinson’s disease. He was 70 years old. Born in...
Nutrition, Muscle Loss Compromises Survival in Patients With Cervical Cancer Undergoing Chemoradiotherapy
A scoping review of cachexia, sarcopenia, and malnutrition in patients with locally advanced cervical cancer undergoing chemoradiotherapy revealed that women who lost at least 10% muscle mass during treatment had a six times higher mortality rate, regardless of their weight at the start of...
A Battle With My Blood
Editor’s note: On November 22, 2025—the 62nd anniversary of her grandfather President John F. Kennedy’s assassination—Tatiana Celia Kennedy Schlossberg published an essay in The New Yorker detailing her diagnosis of acute myeloid leukemia with chromosome 3 inversion, a rare and aggressive subtype...
Deb Schrag, MD, MPH, FASCO, Elected 2027–2028 ASCO President
On December 19, 2025, ASCO announced its members had elected Deb Schrag, MD, MPH, FASCO,as President for the 2027–2028 term. Dr. Schrag will begin her term as President-Elect upon the conclusion of the 2026 ASCO Annual Meeting. Dr. Schrag, a gastrointestinal medical oncologist, is the George J....
New ASCO Guideline Addresses Management of Cancer During Pregnancy, From Diagnosis Through Survivorship
A new ASCO guideline provides recommendations on managing cancer during pregnancy, addressing a range of topics from the selection and timing of diagnostic testing and therapeutic interventions to delivery planning and ethical and legal considerations.1 The guideline aims to inform evidence-based...
Evolving Treatment Landscape Spurs Living Guideline Update on Multiple Myeloma
ASCO, in collaboration with Ontario Health (Cancer Care Ontario), has published an update to their previous guideline on the treatment of multiple myeloma.1 This new guideline—which has been selected as an ASCO Living Guideline—reflects dramatic changes that have helped improve the management of...
Case 3: Metastatic HR-Positive/HER2-Negative Breast Cancer With PTEN Loss and Emergent ESR1 Mutation
This is Part 3 of Balancing Benefit and Burden: Managing Toxicities in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Neil Iyengar, Sara Tolaney, and William Gradishar...
Most Patients Support Use of AI in Mammogram Readings, Survey Reveals
The results of a recent survey showed that patients largely support the use of artificial intelligence (AI) to aid radiologists in reading mammograms. The findings, which were published in Breast Cancer Research and Treatment, also indicated acceptance varied in association with factors such as...
Dual Antigen Targeting of Drug-Resistant Extramedullary Myeloma
In a phase II trial (RedirecTT-1) reported in The New England Journal of Medicine, Kumar et al found that the combination of talquetamab (anti–G protein–coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen) produced high response rates in patients with...
Phased Variant ctDNA as Biomarker After First-Line Treatment in LBCL
In a study (DIRECT) reported in the Journal of Clinical Oncology, Krupka et al found that phased variant (PV) ctDNA provided “sensitive and clinically meaningful response assessment” after first-line treatment of large B-cell lymphoma (LBCL). As stated by the investigators, “Tracking tumor-specific ...
Past NCI Director and ASCO President Elected President of the National Academy of Medicine
Monica M. Bertagnolli, MD, FACS, has been elected by members of the National Academy of Medicine (NAM) as the Academy’s next President. Beginning July 1, 2026, she will succeed Victor J. Dzau, MD, who has served as NAM President since 2014. Dr. Bertagnolli’s election to a 6-year term follows her...
Stephen Lam Chan, MD, FRCP, MRCP, on HCC: Pembrolizumab After Resection or Local Ablation
Stephen Lam Chan, MD, FRCP, MRCP, of the Hong Kong Cancer Institute, The Chinese University of Hong Kong, discusses findings from the phase III KEYNOTE-937 trial, which evaluated the efficacy and safety of pembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC)...
FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials
On January 20, 2026, the U.S. Food and Drug Administration (FDA) released a draft guidance for industry regarding the use of minimal residual disease and complete response as primary endpoints in clinical trials evaluating drugs and biologics for the treatment of patients with multiple myeloma that ...
Popular Supplement May Interfere With Cancer Treatment
For many patients with cancer, hair loss can be one of the most distressing side effects of their therapy. Increasingly, patients have been taking oral supplements of biotin, which are marketed to consumers for their potential to improve hair regrowth and brittle nails. However, there is little...
Investigational Vaccine Could Prevent Cancer Development in Lynch Syndrome Carriers
An investigational cancer vaccine, NOUS-209, has shown potential for intercepting precancerous and cancerous cells before the disease can develop in individuals with Lynch syndrome, thereby showing the potential to prevent cancer from developing in these high-risk individuals, according to findings ...
Regulatory Agencies Establish Principles of Good AI Use in Drug Development
The U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have collaborated with the European Medicines Agency (EMA) to develop a set of 10 guiding principles for good uses of artificial intelligence (AI) in...
HCC: LLM Advice and Treatment Concordance
Commonly used large language models (LLMs) were able to provide appropriate, guideline-aligned treatment recommendations for patients with straightforward cases of early-stage hepatocellular carcinoma; however, greater disagreement with physician recommendations was seen in cases of late-stage...
Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence
Recreational physical activity may be associated with breast tissue composition and oxidative stress levels in adolescent girls, independent of body fat percentages, according to research findings published in Breast Cancer Research. “The importance and urgency of this research are underscored by...
ctDNA Positivity After Neoadjuvant T-DM1 May Predict HER2-Positive Breast Cancer Recurrence
Excluding skin cancers, breast cancer is the most commonly diagnosed cancer among women in the United States, accounting for about 30% of all new female cancers each year. In 2026, the American Cancer Society estimates that 322,000 new cases of invasive breast cancer and about 61,000 new cases of...
Global Cancer Survival Gaps Assessed Using a Country-Level Machine-Learning Framework
A machine-learning model has calculated country-specific cancer mortality-to-incidence ratios and evaluated the factors that contribute the most to each country's survival gaps. Additionally, the artificial intelligence (AI) tool mapped out actions each country could take to improve cancer...
